"Methylene Bridge" to 5-HT 3 Receptor Antagonists: Conformationally Constrained Phenylguanidines

Ahmed S. Abdelkhalek, Genevieve S. Alley, Osama I. Alwassil, Shailesh Khatri, Philip D. Mosier, Heather L. Nyce, Michael M. White, Marvin K. Schulte, Małgorzata Dukat

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT 3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT 3 receptor antagonists. We examined the structure-activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT 3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT 3 receptor antagonist.

Original languageEnglish
Pages (from-to)1380-1389
Number of pages10
JournalACS Chemical Neuroscience
Volume10
Issue number3
DOIs
StatePublished - 20 Mar 2019
Externally publishedYes

Keywords

  • 3D-graphic models
  • binding affinities
  • Dihydroquinazolines
  • functional activities
  • SAR
  • site-directed mutagenesis

Fingerprint

Dive into the research topics of '"Methylene Bridge" to 5-HT 3 Receptor Antagonists: Conformationally Constrained Phenylguanidines'. Together they form a unique fingerprint.

Cite this